ClinicalTrials.gg
CompletedNCT02722967Updated May 23, 2018Results posted

Exploratory Trial to Assess the Functionality of an Integrated Call Center for the Digital Medicine System

A Phase 2 interventional study of Aripiprazole + IEM (Ingestible Event Marker) in Schizophrenia, Major Depressive Disorder and Bipolar I Disorder, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 4 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2018-05-23.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
49
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 126 studies testing aripiprazole in Schizophrenia — 4 open to participants now, 4 under way, 1 of them phase 3. Aripiprazole · Schizophrenia.

Enrollment
93rd of 125
49 · median 130
Started
2016
with 2 others
Phase 2
4 of 126
none open now
Registered
100th of 126
by date
Lead sponsor
44 of 126
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 126 studies testing aripiprazole in Schizophrenia, this one is the 93rd largest by enrollment of the 125 interventional ones that give a count, is one of 3 that started in 2016, is one of 4 in phase 2, and was the 100th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

4 of the 126 studies testing aripiprazole in Schizophrenia are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About aripiprazole

Aripiprazole: first FDA approval 2002 (ABILIFY), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 126 studies testing aripiprazole in Schizophrenia, or all of them as a file.
02

Study summary

This study will assess the helpfulness of the integrated call center in optimizing use of the Digital Medicine System in adult subjects with Schizophrenia, Major Depressive Disorder, or Bipolar Disorder taking oral aripiprazole.

Read the detailed description

The Digital Medicine System includes a drug-device combination of aripiprazole + an ingestible event marker (IEM), a wearable sensor (skin patch), and application software to convey the level of activity and rest, and to mark events through the act of ingestion.

Physician and self-report are the most commonly used to assess medication compliance yet studies have consistently found that healthcare providers' subjective judgments of medication compliance are often inaccurate, with a tendency for practitioners to overestimate subject adherence. The sponsor's intent is to develop a system that will benefit future subjects by providing the ability to measure their medication-taking behavior in an objective manner and being able to monitor several physiologic parameters.

03

Conditions studied

  • Schizophrenia
  • Major Depressive Disorder
  • Bipolar I Disorder
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Primary diagnosis of Schizophrenia (SCH), Major Depressive Disorder (MDD), or Bipolar 1 Disorder (BP1), per the , Fifth Edition (DSM-5)
  • Must be able to swallow tablets
  • Currently taking a stable daily dose of oral aripiprazole
  • Must have capacity to utilize the technology
  • Skin in area of patch application must be free of any skin disorders or dermatological problems

Exclusion criteria

Exclusion Criteria:

  • Subjects using long acting injectable antipsychotic medications
  • Subjects likely to be incapable of using the Digital Medicine System even with assistance
  • Subjects who present serious risk of suicide
  • History of epilepsy or seizures
  • History of to antipsychotic agents, adhesive tape or any component of the sensor skin patch or ingestible event marker
  • Current history of substance use disorder meeting criteria
  • Subject with unstable mood, acute psychosis or exhibiting symptoms requiring hospitalization
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
49 participants (actual)

Study arms

  • Experimental
    Aripiprazole + IEM

    Subjects will receive an intervention consisting of a drug-device combination that consists of an aripiprazole tablet with a tiny sensor embedded within it referred to as an Ingestible Event Marker (IEM) . They will discontinue their normally prescribed oral aripiprazole tablets and will take the aripiprazole(2, 5, 10, 15, 20, or 30 mg) + IEM once daily for the 8-week assessment period for this trial.

    Drug: Aripiprazole + IEM (Ingestible Event Marker)

Interventions

  • DrugAripiprazole + IEM (Ingestible Event Marker)

    Drug page: Aripiprazole

    Oral aripiprazole (2, 5, 10, 15, 20, or 30 mg) with an ingestible event marker in a single daily dose for duration of the trial.

    Also known as: MIND1, Digital Medicine System

06

What researchers measure

Primary outcomes

  1. Assessment of the Functionality of an Integrated Call Center for DMS by Adult Subjects With SCH, MDD, or BP1 Who Were Treated With Oral Aripiprazole.

    The primary outcome was assessed as the establishment of a functional and operational integrated call center with coordinated feedback to the subject and investigative site to optimize the use of DMS as measured by: 1. Inbound calls (ie, calls from the subject to the integrated call center) by help type; 2. Outbound calls (ie, calls from the integrated call center to the subject) by help type. The number presented in the table is the number of subjects in trial who made (inbound) or received (outbound) calls

    Time frame: From baseline upto week 9

07

Results

Posted May 23, 2018

Participant flow

This open-label, single-arm trial assessed the functionality of an integrated call center for digital medicine system (DMS) as used by adult subjects (18 to 65 years of age, inclusive, at the time of screening) with Schizophrenia (SCH), Bipolar 1 disorder (BP1), or Major depressive disorder (MDD) being treated with oral aripiprazole.

Participant flow — Overall Study
MilestoneBipolar 1 Disorder (BP1)Major Depressive Disorder (MDD)Schizophrenia (SCH)
Started221215
Completed171011
Not completed524
Withdrew: Adverse event100
Withdrew: Lost to follow-up010
Withdrew: Non-compliance with patch wearing211
Withdrew: Withdrawal by subject101
Withdrew: Physician decision100
Withdrew: Non-adherence of the patch to the skin002

Outcome measures

PrimaryAssessment of the Functionality of an Integrated Call Center for DMS by Adult Subjects With SCH, MDD, or BP1 Who Were Treated With Oral Aripiprazole.

The primary outcome was assessed as the establishment of a functional and operational integrated call center with coordinated feedback to the subject and investigative site to optimize the use of DMS as measured by: 1. Inbound calls (ie, calls from the subject to the integrated call center) by help type; 2. Outbound calls (ie, calls from the integrated call center to the subject) by help type. The number presented in the table is the number of subjects in trial who made (inbound) or received (outbound) calls

Time frame:
From baseline upto week 9
Reported as:
Number · participants
Assessment of the Functionality of an Integrated Call Center for DMS by Adult Subjects With SCH, MDD, or BP1 Who Were Treated With Oral Aripiprazole.
participantsBipolar 1 Disorder (BP1)Major Depressive Disorder (MDD)Schizophrenia (SCH)
Inbound, Baseline001
Inbound, Week 1889
Inbound, Week 2746
Inbound, Week 3213
Inbound, Week 4425
Inbound, Week 5424
Inbound, Week 6036
Inbound, Week 7133
Inbound, Week 8204
Inbound, Week >8001
Outbound, Baseline000
Outbound, Week 1221215
Outbound, Week 2221215
Outbound, Week 3643
Outbound, Week 4634
Outbound, Week 5532
Outbound, Week 6725
Outbound, Week 7944
Outbound, Week 8755
Outbound, Week >8420

Adverse events

Collected over 9 Weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Bipolar 1 Disorder (BP1)0/22 (0%)0/22 (0%)10/22 (45.5%)
Major Depressive Disorder (MDD)0/12 (0%)0/12 (0%)9/12 (75%)
Schizophrenia (SCH)0/15 (0%)0/15 (0%)1/15 (6.7%)
Most frequent other events
Showing 10 of 12
Most frequent other events
EventBipolar 1 Disorder (BP1)Major Depressive Disorder (MDD)Schizophrenia (SCH)
RashSkin and subcutaneous tissue disorders5/226/120/15
ErythemaSkin and subcutaneous tissue disorders2/220/120/15
SinusitisInfections and infestations0/221/120/15
Upper Respiratory Tract InfectionInfections and infestations1/221/120/15
Meniscus InjuryInjury, poisoning and procedural complications0/221/120/15
SunburnInjury, poisoning and procedural complications0/221/120/15
HeadacheNervous system disorders1/221/120/15
SyncopeNervous system disorders0/221/120/15
PruritisSkin and subcutaneous tissue disorders1/221/120/15
Skin IrritationSkin and subcutaneous tissue disorders0/221/120/15

Baseline characteristics

Intent-to-treat (ITT) Sample: All subjects who entered the trial and used Digital Medicine System (DMS).

Age, Continuous
Age, Continuous(years)Bipolar 1 Disorder (BP1)Major Depressive Disorder (MDD)Schizophrenia (SCH)Total
Mean45.5 ± 15.249.3 ± 11.245.5 ± 11.146.4 ± 13.0
Sex: Female, Male
Sex: Female, Male(Participants)Bipolar 1 Disorder (BP1)Major Depressive Disorder (MDD)Schizophrenia (SCH)Total
Female157931
Male75618
08

Study locations

4 sites
  • Granada Hills, California 91344, United States
  • Rochester, New York 14603, United States
  • Durham, North Carolina 27714, United States
  • Richmond, Virginia 23230, United States
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2016, a primary completion of Sep 2016 and a completion of Sep 2016. It does not say whether these dates are actual or estimated.

Results were first posted in May 2018, 1 year 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2016
First posted
Mar 30, 2016
Start
Mar 2016
Primary completionActual
Sep 2016
CompletionActual
Sep 2016
Results first posted
May 23, 2018
Last update
May 23, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 23, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02722967
Responsible party
Sponsor
First posted
Mar 30, 2016
Start date
Mar 2016
Primary completion
Sep 2016
Completion
Sep 2016
Results posted
May 23, 2018
Last update
May 23, 2018

Study contacts

Tim Peters-Strickland, M.D.
study director · Otsuka Pharmaceutical Development & Commercialization, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aripiprazole

Start the discussion